Global Research
So far, all of the drugs developed against COVID-19 have been disastrous in one way or another. Remdesivir, which to this day is the primary COVID drug approved for use in U.S. hospitals, routinely causes severe organ damage and, often, death
Despite that, the U.S. Food and Drug Administration has approved remdesivir for in-hospital and outpatient use in children as young as 1 month old
Another COVID drug, Paxlovid, will in some cases cause the infection to rebound when the medication is withdrawn
Molnupiravir (sold under the brand name Lagevrio) also has serious safety concerns. Not only might it contribute to cancer and birth defects, it may also supercharge the rate at which the virus mutates inside the patient, resulting in newer and more resistant variants
The fact that U.S. health authorities have focused on these drugs to the exclusion of all others, including older drugs with high rates of effectiveness and superior safety profiles, sends a very disturbing message. They’ve basically become extensions of the drug industry, protecting the drug industry’s interests at the cost of public health
[…]
Despite its horrible track record, the U.S. government actually pays hospitals a 20% upcharge for sticking to the remdesivir protocol, plus an additional bonus.6,7,8 Hospitals must also use remdesivir if they want liability protection.
Incentives like these have turned U.S. hospitals into veritable death traps, as more effective and far safer drugs are not allowed, and hospitals are essentially forced to follow the recommendations of the U.S. Centers for Disease Control and Prevention. As reported by Forbes science reporter JV Chamary back in January 2021, in an article titled, “The Strange Story of Remdesivir, a COVID Drug That Doesn’t Work”:9
[…]
Based on interim results from studying more than 5,000 participants, the international study concluded that remdesivir ‘had little or no effect on hospitalized patients with COVID-19, as indicated by overall mortality, initiation of ventilation, and duration of hospital stay.’ As a consequence of being mostly ineffective, WHO recommends against the use of remdesivir in COVID-19 patients.”
Shockingly, US Approves Remdesivir for Babies
Curiously, while Big Tech — aided and abetted by the U.S. government — has spent the last two years censoring and banning any information that doesn’t jibe with the opinions of the WHO, the U.S. government has completely ignored the WHO’s recommendation against remdesivir.
[…[
Post-Paxlovid COVID Rebound
As reported by Bloomberg,18 COVID patients treated with a five-day course of Paxlovid sometimes experience severe rebound when the medication is withdrawn.19 U.S. government researchers are now planning to study the rate and extent to which the drug is causing SARS-CoV-2 infection to rebound, and whether a longer regimen might prevent it.
[…]
“Providers who are going to be prescribing this should be aware that this phenomenon occurs, and if people have symptoms worsening after Paxlovid, it’s probably still COVID. The big problem is that when this drug was released, this information wasn’t included [on the label].”
[…]
Molnupiravir Supercharges Viral Mutation
Molnupiravir (sold under the brand name Lagevrio) also has serious safety concerns. This drug was developed by Merck and Ridgeback Therapeutics and approved for emergency use by the FDA December 23, 2021, for high-risk patients with mild to moderate COVID symptoms.
However, not only might it contribute to cancer and birth defects, it may also supercharge the rate at which the virus mutates inside the patient, resulting in newer and more resistant variants.24 As reported in November 2021 by Forbes contributor and former professor at Harvard Medical School, William Haseltine, Ph.D.:25
“… I believe the FDA needs to tread very carefully with molnupiravir, the antiviral currently before them for approval. My misgivings are founded on two key concerns.
The first is the drug’s potential mutagenicity, and the possibility that its use could lead to birth defects or cancerous tumors. The second is a danger that is far greater and potentially far deadlier: the drug’s potential to supercharge SARS-CoV-2 mutations and unleash a more virulent variant upon the world …
[…]
Experts Question Usefulness of Molnupiravir
More recently, in a January 10, 2022, article, Newsweek cited concerns by professor Michael Lin of Stanford University:27
“’I am very concerned about the potential consequences now that molnupiravir has been approved … It would only be a matter of time, perhaps a very short time, before a lucky set of mutations occurs to create a variant that is more transmissible or immunoevasive …
[…]
The Most Revolutionary Act 
Remdesevir is poison. Giving this to anyone, let alone children will lead to many deaths. This is murder!
LikeLike
The practice of medicine has change so much since I was in medical school I can hardly recognize it.
LikeLike